SMMT Stock Hub: Summit News, Ivonescimab and FDA Review

November 6 research update: Summit expands ivonescimab combinations beyond lung cancer

SMMT stock: dated key data

Financial baseline: September Form 10-Q and Q3 release. Financing completion: AstraZeneca October 5 disclosure. Shares: Q3 Form 10-Q cover. Clinical analysis: September HARMONi update. Price: Nasdaq. Historical liquidity and completed financing do not prove current cash after spending.

Common equity value at the reference close, a Merlintrader calculation: $16.33 (November 6, 2026 Nasdaq close) × 799,763,918 reported common shares (Q3 Form 10-Q cover, October 30) = approximately $13.06 billion; a computed illustration from stated figures, not a disclosed market capitalization.

SMMT today: financing, regulatory evidence and broader trials

The July filing’s substantial-doubt funding assessment predated the completed AstraZeneca investment. In its Form 10-Q for the quarter ended September 30, filed November 4, Summit states that, with the $2.0 billion received from AstraZeneca after quarter-end, its cash, cash equivalents and short-term investments are sufficient to fund operating cash needs for at least 12 months from the issuance of the financial statements. Cash, cash equivalents and short-term investments were $629.8 million at September 30; operating activities used $423.2 million in the first nine months, and third-quarter ATM sales raised $94.1 million gross, with about $354.3 million of ATM capacity left at September 30. The financing changes the resources available for development without resolving the FDA evidentiary question. Preferred conversion, ATM sales and later spending still affect common holders. Q3 Form 10-Q · Q3 release · Preferred terms.

On November 4 Summit also filed a prospectus supplement registering the possible resale by AstraZeneca of up to 108,955,369 common shares issuable on conversion of its preferred stock, under the registration rights agreed at closing. Summit is not selling shares under that supplement and will receive no proceeds. The preferred stock and the common shares issuable on conversion are subject to a one-year lock-up after the October 5 closing. In the supplement’s calculation, the conversion shares equal 12.0% of the total, based on 799,763,918 shares outstanding at October 30 plus the conversion shares. Prospectus supplement · Form 8-K · Lock-up terms in the Q3 Form 10-Q.

HARMONi’s original overall-survival co-primary test missed statistical significance. The June filing describes FDA’s communication that statistically significant OS was necessary and that PFS might not suffice. Later nominal follow-up does not change the original prespecified result; the China biliary-tract study tests a different population and indication. FDA and trial disclosure · HARMONi follow-up · HARMONi-GI1 results.

SMMT stock news: six selected updates

SMMT stock catalysts: dated milestones

• November 4, 2026 · Special shareholder meeting and Q3 resultsCompleted · authorized shares raised to 2 billion

  Stockholders approved the increase from 1 billion to 2 billion authorized common shares; conversion of AstraZeneca’s preferred stock also requires HSR clearance. Third-quarter results were reported the same day. Form 8-K · Q3 release.

• November 14, 2026 · Ivonescimab FDA goal action dateReview target · post-TKI EGFR-mutated NSCLC application

  Acceptance for review does not determine approval or label. Summit plans a conference call after the FDA action. Company-filed acceptance announcement.

• Q4 2026 · EA2251 U.S. site activationCompany expectation · not a trial readout

  The biliary-tract trial is distinct from China GI1 and the lung-cancer application. Collaboration release.

• Q4 2026 · HARMONi-3 squamous cohortCompany expectation · event count, not a disclosed result

  Summit expects the number of PFS events needed for the primary analysis of the squamous cohort to be reached in Q4 2026, with a planned early interim OS analysis alongside it. Q3 release.

• H1 2027 · HARMONi-3 interim OS and non-squamous PFS eventsCompany expectations

  An interim OS analysis independent of PFS is planned for H1 2027; the non-squamous cohort is expected to reach the events needed for its PFS analysis in the same half. Q3 release.

• 2027 · HARMONi-7 and HARMONi-GI3 enrollmentCompany expectations · not readouts

  HARMONi-7 enrollment is expected to complete in 2027, and enrollment in the 900-patient HARMONi-GI3 study in Q3 2027. Q3 release.

SMMT HARMONi evidence and the separate HARMONi-GI1 setting

GI1 was single-region, with data generated, managed and analyzed by Akeso. Serious treatment-emergent adverse events were 43.4% versus 43.7% in that study; its favorable OS result does not imply absence of safety risk or automatic global generalizability. Ivonescimab remains investigational in Summit’s licensed territories in the reviewed announcements. GI1 methods and safety · HARMONi update.

SMMT preferred shares, Akeso license economics and funding

The $2B investment was completed October 5. Conversion of the preferred shares would add approximately 108.955M common shares under the terms, rather than produce another $2B of proceeds. Common-share authorization is capacity and does not itself establish issuance. Options and any later ATM activity are additional considerations.

Akeso’s license provides low double-digit royalties and up to $4.555B of contingent milestones. Those maximum milestones are not all current liabilities; actual events, territories and sales determine payments. Trial spending and manufacturing dependence remain alongside the expanded development plan.

The June filing describes a European patent opposition with historical procedural details. That disclosure does not prove a current decision invalidating the patent or a favorable final outcome. License, capital and legal disclosures · Preferred investment terms · Investment completion.

Merlintrader Health Score · SMMT

Assessed November 6, 2026. 4×30% + 3×30% + 2×20% + 3×10% + 4×10% = 3.20/5. A robustness assessment, not FDA odds, a valuation or a recommendation.

SMMT red flags

• The original HARMONi OS co-primary test missed significance; later tests are nominal.
• GI1 is a different indication and China-sponsored evidence, not the U.S. application outcome.
• FDA acceptance, a goal date and strategic financing do not guarantee approval.
• The July going-concern assessment is historical and predates October financing; in its Q3 Form 10-Q, filed November 4, Summit concludes that with the AstraZeneca investment its cash covers operating needs for at least 12 months from issuance of the financial statements.
• Preferred conversion adds common shares without providing another $2B.
• Royalties, event-based milestones, trial spending and manufacturing dependence remain.
• Research agreements and study openings do not prove efficacy or approved patient selection.